Year End Performance Numbers?
With the year coming to a close, let's compile some YE numbers across the industry. I'll start:
Tudor +5%
Brevan Howard +0%
Balyasny +7%
Citadel Wellington +20%
Marshall Wace +24%
Winton +9%
Alphadyne and Rokos both down double digits.
Anyone have others to add?
Hey Analyst 3+ in HF - RelVal, I think you deserve a response...heck, everyone does. We're listening, sorry about the delay ...my best guess at places on WSO that could help:
More suggestions...
Hope that helps.
D1: + 17% through November
Is D1 net long and curious how much of that is privates vs public equities? The privates business is a great way to mask the public side.
That stat is for c.35% invested in privates. Definitely net long.
D1 gave up shorting this year / they do very very little of it. Team is mostly focused on longs
these guys also got smacked in december (-12%)
Apollo L/S Credit +12%
(was +26% in 2020)
Not bad for a credit fund
Renaissance (RIEF, don't have medallion) + 8.9%
Elliott +12.9%
Third Point +26.3%
Trian +4.8%
Starboard +11.8%
Millenium +11.9%
Do you know the following funds - soroban, darsana, Appaloosa, Skye?
do not, sorry!
Anyone have info on Matrix, Abdiel, or Pershing Square?
Abdiel: -6% as of 11/30.
Abdiel is getting crushed, CRCT/FSLY/GDRX are all down bad
Honestly surprised they are just down 6%
Rooks: - 26%
Alphadyne: -22%
Brevan Howard: -11%
Systematica Macro: -12%
Solitude: -11%
Pharo Trading: -13%
Zeal China: -10%
Element: -9%
Melvin: -44%
Archegos: Bankrupt
Tudor: +5%
Marhsall Wace Tops: + 24%
Balyasny: + 7%
Pershing Square: + 15%
Not trying to be a smartass, genuinely curious about how many of these funds produce such dismal returns in a year where the S&P is up almost 30%.
Many of these (rokos, brevan Howard, element, alphadyne, etc) are macro funds. So they generally will have more bond and maybe FX bets. Unlike funds that invest within equities (L/S, etc) that may have a net long US equity position, these funds may not even invest in US equities. That’s not to say they couldn’t have loaded up on equities, but generally not their speciality (and not something they would have net exposure to).
As Matt Levine rightly says, HFs are a compensation structure not an asset class.
What happened to Melvin?
GME happened lol
Where did you source this
HSBC hedge fund weekly
Tiger +3%
Lone Pine -2%
Viking -6%
All YTD Nov
Do you know how Viking did in 2020? As well as tiger / lone pine?
Think Viking was +52%, Lone Pine +30% and Tiger +43% for 2020
.
are these only for their public book or do they incorporate private valuations as well? i believe lone pine and viking do crossover investing out of the same funds
No idea…
Lone pine does crossover investing out of the same find although its a very small amount of assets, something like 5 percent i think and viking has a separate fund for investing in privates. I also believe that vikings returns posted here are public and private combined and I know that they returned something like 25 percent in their public hedge fund last year. Besides with the kind of tight ship they run and with the kind of leverage they use, would be close to impossible to return 50+ in their public markets vehicle. In fact apart from their founding year they've never had more than 22 percent returns up until now
no way lone pine is down...
very interesting that the three firms that WSO users likely wet dream over the most have had these returns (two in the red!) when the S&P's up 28%. mindboggling
Thats what you get for being overly reliant on tech for returns
In one year. What’s their AUMs and long and medium term returns again?
The schadenfreud towards the firms at the absolute top of the food chain is so comically transparent.
There’s tons of arm chair quarterbacks falling all over themselves whenever Tom Brady throws a 15 yard pass that thunks off the turf. He’s still Tom Brady and you’re still… no body.
Ytd through nov
Senvest Equity 75%
Impala** Equity 55.5%
SRS Equity 46%
Third Point Event driven 25.7%
Citadel Wellington*** Multistrategy 24.3%
Heard Capital Equity 23%
Pershing Square Equity 20.1%
Voleon Investors* Quant 19%
Citadel Tactical Trading Multistrategy 18.1%
D1 Capital Equity 17%
Hudson Bay International Multistrategy 14.1%
Renaissance Institutional Equities* Quant 13.7%
Schonfeld Strategic Partners Multistrategy 12.6%
Millennium Management Multistrategy 12.1%
Renaissance Institutional Diversified Alpha* Quant 11.3%
Voleon Institutional Strategies International* Quant 11%
Carlson Double Black Diamond Multistrategy 10.1%
Two Sigma Compass Macro 8.8%
Coatue Qualified Partners Equities 8.8%
Verition* Multistrategy 8%
Point72 Multistrategy 7.4%
Renaissance Institutional Diversified Global Equities* Quant 7.4%
Balyasny Atlas Enhanced Multistrategy 7.3%
Carlson Black Diamond Arbitrage Event driven 7%
Voloridge Trading Aggressive Quant 5.9%
Sculptor Master Multistrategy 4.8%
ExodusPoint Multistrategy 3.2%
Tiger Global Equity 3%
Two Sigma Spectrum Quant 3%
Bridgewater Pure Alpha II Macro 0.3%
Lone Pine Cypress Equity -1.9%
Voloridge Quant -3.9%
Viking Global Equities Equity -6.1%
Brevan Howard AS Macro -7.4%
Element Macro -8.1%
Alphadyne Macro -22%
Rokos Macro -25%
Melvin Capital Equity -41.5%
Any info on Cincitive, Holocene, Woodline for November?
Holocene up roughly 2.5%, Woodline up a little over 9%.
EDIT: these are YTD figures through November.
Senvest: thank you dumb Gamestop money
Would be very interested in hearing if people know which funds are net long (and by how much) versus market neutral. If not it seems tough to compare returns. Eg: Citadel vs Pershing at 20%+ each. Surely Citadel’s returns are higher quality given the beta neutral product (just my view).
Anyone know Maverick? They had a decent sized GME position too
Would be interested in Biotech fund returns (i.e. Perceptive, Cormorant, Orbimed, etc.) after seeing the WSJ article. Rumor has it couple are down 70%+ YTD after record breaking 2019/2020 returns. Been a brutal market for anyone with small cap healthcare exposure, and a couple of fund liquidations. Expect more to come in 2022…
RTW -10.5% with privates, -17% without. Avoro -13% (but +10% through Dec). Cormorant -45% and RA -4% (not sure if they include privates, but suspect yes). I would suspect Perceptive probably -30-35%. Last I heard Orbi -25-30% but lacking Dec data.
when a SM like lone pine returns -3% for the year, how do bonuses generally work? would it just come out of the mgmt fees? assuming they're fugal with their expenses. doubt anyone would just be taking home their base salaries ($100k).
Management fees and the company’s balance sheet. You can’t be frugal with expenses and still pay employees well if people’s comp is the number 1 expense by far. Probably not getting paid just 100k but it’s simple economics - if there’s no PnL, there’s no money to go around this year and people don’t get paid big money. Lone Pine employees don’t get paid a shit ton because they work at Lone Pine. They get paid a shit ton because they make money at a lean fund.
In general management fees are enough to pay out “standard” bonuses for all junior/mid tenured people. As someone mentioned, you don’t want to lose talent over a few 100k. The people that get hit harder (relative to normal years, since they’ll still make solid $) during the down years are those with large equity stakes (so the senior people who are aiming to take down 7-8 figures) and the people with high comp packages
So downside case (0% or less), analyst at a lone pine type fund clips $500-700k, base case (10% return or more) $1-2mm, and upside case (25%+) 3mm+?
Lol the better question is how melvin’s bonuses will work this year when they’re down 42%
Plotkins pockets
Raised new money for exactly that purpose
Problem is less this year and more next (although clearly a problem in the current year as far as having enough capital to reverse losses, etc). On a big down year like that you are lucky if the fund survives the redepemtions, it’ll depend on how convincing they are that they can turn it around and maybe more importantly what lock up agreements (if any) they have. Year end tends to be a time when clients can redeem, so the down 40 isn’t the problem, it’s the 90% of the clients pull their money.
they have a bunch of deferred comp from prior years right?
Depends on the fund, mostly likely, yes, there is some deferred. Not all funds structure it this way, but if they have a structure where you defer payouts (for that year’s performance) then that helps keep people around. The problem is the forward looking bonuses when there are very bad years, which 3% down isn’t a huge deal (unless a new plan is in place to deal with the high water mark). The other thing to note is that almost always competitors will pay that off if they want you.
A fund like Lone Pine has massive scale on a mgmt fee/fte basis. People are still getting paid well, just not a big year. Finger in the air, maybe 400-600k for a relatively junior analyst and prob atleast a million bucks or more for more tenured sr analyst/partner level folks.
The smaller firms that don’t have this sort of scale are where this gets much trickier. In that case the founders do what they can to keep people they value. Pay out of their pocket, pay with titles, give incremental points in incentive fee in future years, etc.
How is Ackman only up 15? Didn't he make a few billion?
believe it was in 2020 with CDS during Covid
How are Grant Wonders and Jamie Sterne doing?
Did Grant even launch yet?
yup, launched Q2 2021, iirc
https://www.reuters.com/business/finance/top-hedge-funds-earn-record-65…
TCI with 23%...pretty crazy at their size
Does anyone have the TCI data? thanks in advance
Et ut minus minus sed. Cumque labore iure facilis porro nesciunt fugiat consequuntur. Maiores consequatur aut placeat expedita sit enim.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...
Perspiciatis sint alias nesciunt veniam ut. Qui omnis quo aut illum velit id quo. Voluptatem non neque ex qui omnis quaerat.
Sed numquam et voluptatibus aut corporis explicabo. Quidem amet nisi est vel. Dicta consequatur dolorem aut voluptate.
Distinctio ea incidunt non quis quod asperiores. Laudantium et est fuga sit.
Sunt placeat tempora expedita tenetur. Id totam rerum tempora et nesciunt deserunt culpa. Nemo numquam qui fugiat vel et autem. Voluptatem quam qui error voluptatem et aperiam nobis aut.
Earum fuga dolore quaerat eos quia eius. Dolor voluptatum qui nulla autem. Et quo est at aut veniam. Repudiandae eveniet sint sit quis esse quaerat.
Adipisci sit et nostrum officia accusamus cupiditate quos. Illo facere ab et similique ducimus.
Tempora mollitia qui et sed. Magni labore nihil quidem ex ad laborum repudiandae fuga.